We’re proud to announce a strategic collaboration with Prevail Therapeutics, a subsidiary of @EliLillyandCo, that will leverage Scribe's #CRISPR X-Editing (XE) technologies to accelerate novel in vivo therapies for neurological and neuromuscular diseases.

No patient should be left behind. Millions in the U.S. can't wait. Our CEO @BenjaminLOakes joined the @NPLB_org campaign to share the importance of our work creating & advocating for next-gen medicines, including #CRISPR-based therapies for cardiovascular disease. Learn more ⬇️.

Check out the @GENbio article with quotes from Scribe co-founders @BenjaminLOakes and Jennifer Doudna, plus Fyodor Urnov and Kiran Musunuru: 🔗 More on how we’re making genetic medicines accessible and transformative for patients:

Thanks @xiaofei_lin for highlighting Scribe’s work and conviction in changing the medical paradigm for the better—from advancing the leading epigenetic silencing therapy targeting PCSK9 to reduce LDL-C, to partnering with leading drug developers such as @EliLillyandCo & @sanofi.

“In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients is going anywhere.” – @BenjaminLOakes, Scribe CEO in @GENbio on delivering the full promise of #CRISPR. Read more here and our 🧵:

It’s Day 1 of #BIO2025! Join our CBO Svetlana Lucas this afternoon as she takes the stage for a panel discussion on what to know about partnering early in biopharma. The session starts at 3 p.m. ET in Room 210A. Don’t miss it! ⬇️. @IAmBiotech.

Kick off #BIO2025 week with our CBO Svetlana Lucas as she joins biopharma leaders to discuss what makes a platform or modality partnerable—to ultimately bring next-generation therapies to patients. More details 👉

We're excited to attend #BIO2025!. Reach out to set up a meeting with us if you're interested in collaborating to rewrite the story of disease and hearing the latest updates on our #CRISPR genome and epigenome editing technologies and pipeline 👉

RT @blalpert: Beyond Statins. Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.

Thanks to @blalpert for the shoutout. Read his article on new innovations for treating cardiovascular disease here: And check out our recent thread for the latest data on our epigenetic silencing technology ELXR:

In this feature, @barronsonline highlights that “genetic-medicine approaches to PCSK9 are exploring nonpermanent, but long-lasting fixes . Scribe Therapeutics has reported intriguing results in monkeys from ‘epigenetic’ edits of the molecules that turn genes on and off.”.

🧬 #GeneEditing: At ASGCT, we showcased Scribe’s highly engineered genome editor, XE, as a promising approach to address muscular dystrophies such as Duchenne Muscular Dystrophy. Learn more: #CRISPR.

📊 #EpigeneticEditing: At EAS, our late-breaker spotlighted that Scribe’s novel epigenetic silencer, ELXR, achieves 9+ months of >50% LDL-C reduction in non-human primates ➡️ surpassing the current standard of care therapies for LDL-C lowering.

This month, we presented positive data on our #CRISPR technologies at the 2025 @EASCongress and @ASGCTherapy Annual Meeting. For more details, read our thread and press release below 👇

@EliLillyandCo @ASGCTherapy Our second #ASGCT2025 presentation takes place this afternoon. This joint session with @EliLillyandCo’s Prevail will cover:. ➡️Novel self-inactivating AAV technology we've engineered featuring Scribe’s X-Editor.➡️Our results applying this tech to in vivo editing in the mouse CNS.

And coming up tomorrow: Our joint presentation with @EliLillyandCo’s Prevail Therapeutics!. For more details: @ASGCTherapy.

Attending #ASGCT2025 🧬 in New Orleans?. Be sure to check out our first presentation today on novel #CRISPR genome editing strategies using our X-Editor (XE) technology to target mutations in Duchenne Muscular Dystrophy. 👇

For more details on our #ASGCT2025 presentations, read our press release:

Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS. 📅 Thursday 5/15 at 5:30 pm.💡 Our joint presentation with Prevail highlighting novel self-inactivating AAV technology from our collaboration.

Advancing the Novel CasX-Editor for Precise Genome Editing to Address Muscular Dystrophies. 📅 Wednesday 5/14 at 5:30 pm.💡 Use of our #CRISPR X-Editor (XE) technology to target mutations in DMD.

Join us at the upcoming @ASGCTherapy Meeting – we will have two presentations showcasing our ongoing advances to engineer novel in vivo genetic medicines, including a joint session with Prevail Therapeutics (a part of @EliLillyandCo’s Gene Therapy Division). Details below 🧬